Jared Weiss, MD, recounts experiences from early in his career that mark the progression of advances in the philosophy of treating early-stage non–small cell lung cancer (NSCLC). Dr Weiss describes witnessing debates over the merits of using adjuvant therapy in residency and the difficulty in communicating its benefit to patients as fellow.
Dr Weiss fast-forwards to the present day, where he now observes a transformative change in how the data on neoadjuvant or perioperative immunotherapy is viewed and accepted, eliminating controversies in treatment decisions, and highlighting the significant progress made for early-stage patients compared with the past decade.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Experiencing the Evolution of Early-Stage Non-Small Cell Lung Cancer Treatment - Medscape - Jan 08, 2024.
